Rise of GLP-1 use for the treatment of obesity and their accessibility across various socioeconomic groups

The increasing prevalence of obesity has prompted the exploration of novel therapeutic options, with glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1RA) emerging as a promising therapeutic option. These agents were initially developed for type 2 diabetes management and have demonstrated significant efficacy in reducing body weight and improving metabolic parameters in several clinical trials conducted worldwide. However, the accessibility of GLP1RA treatments varies across different socioeconomic groups, with disparities in uptake observed among individuals from lower-income backgrounds, racial/ethnic minorities, and those with limited health literacy. Factors contributing to these disparities include financial constraints, suboptimal health insurance coverage, and systemic barriers within healthcare systems. Addressing these inequities requires a multifaceted strategy involving policy changes, price reductions, and targeted educational initiatives to ensure equitable access to GLP1RA therapies. By implementing these measures, healthcare systems can enhance the societal benefits of GLP1RA treatments and improve outcomes for diverse patient populations